Eyepoint Pharmaceuticals (EYPT) Competitors $11.55 -0.18 (-1.53%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$11.70 +0.15 (+1.34%) As of 10/16/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, ALNT, AEHR, TRNS, CTKB, LAB, FEIM, SENS, QSI, and MASSShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Allient (ALNT), Aehr Test Systems (AEHR), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Frequency Electronics (FEIM), Senseonics (SENS), Quantum-Si (QSI), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors 10x Genomics Allient Aehr Test Systems Transcat Cytek Biosciences Standard BioTools Frequency Electronics Senseonics Quantum-Si 908 Devices Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings. Do institutionals and insiders have more ownership in EYPT or TXG? 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, EYPT or TXG? Eyepoint Pharmaceuticals has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Is EYPT or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 10x Genomics' return on equity of -12.88% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eyepoint Pharmaceuticals-337.93% -63.80% -50.72% 10x Genomics -13.13%-12.88%-10.03% Which has higher valuation and earnings, EYPT or TXG? Eyepoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyepoint Pharmaceuticals$43.27M18.40-$130.87M-$2.68-4.3110x Genomics$610.78M2.52-$182.63M-$0.70-17.69 Do analysts rate EYPT or TXG? Eyepoint Pharmaceuticals presently has a consensus target price of $28.33, indicating a potential upside of 145.31%. 10x Genomics has a consensus target price of $13.65, indicating a potential upside of 10.29%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.7110x Genomics 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38 Does the media refer more to EYPT or TXG? In the previous week, 10x Genomics had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 19 mentions for 10x Genomics and 14 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.68 beat Eyepoint Pharmaceuticals' score of 0.51 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summary10x Genomics beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$808.52M$3.41B$6.09B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-4.3122.9385.0727.19Price / Sales18.40486.15604.99132.96Price / CashN/A46.9737.8662.13Price / Book2.3410.5012.396.65Net Income-$130.87M-$52.47M$3.32B$276.79M7 Day Performance-14.89%2.90%2.30%1.75%1 Month Performance-15.32%15.36%9.67%5.15%1 Year Performance3.59%14.29%73.80%36.96% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals2.3941 of 5 stars$11.55-1.5%$28.33+145.3%+2.4%$808.52M$43.27M-4.31120News CoverageTXG10x Genomics4.0556 of 5 stars$11.60+1.1%$13.65+17.7%-21.3%$1.43B$610.78M-16.571,240Trending NewsAnalyst ForecastAnalyst RevisionALNTAllient2.6862 of 5 stars$48.25+5.1%$35.00-27.5%+160.0%$778.04M$529.97M56.102,525AEHRAehr Test Systems1.9968 of 5 stars$25.52+8.6%$24.00-6.0%+87.8%$704.85M$58.97M-116.0090TRNSTranscat3.6689 of 5 stars$69.86+2.0%$112.20+60.6%-45.7%$638.31M$278.42M48.851,245Positive NewsCTKBCytek Biosciences1.8373 of 5 stars$3.96+2.9%$5.60+41.4%-25.0%$489.81M$200.45M-79.20500LABStandard BioTools2.6189 of 5 stars$1.29+0.8%$1.55+20.2%-31.7%$488.95M$174.43M-4.03620News CoverageFEIMFrequency Electronics2.7938 of 5 stars$37.44+5.4%$43.00+14.9%+179.1%$346.29M$69.81M16.35200SENSSenseonics1.9092 of 5 stars$0.42-0.2%$1.54+266.8%+21.5%$341.51M$25.47M-3.2290QSIQuantum-Si2.5778 of 5 stars$2.08+24.6%$3.48+67.1%+211.1%$338.17M$3.06M-3.06150Options VolumeGap UpHigh Trading VolumeMASS908 Devices1.3338 of 5 stars$7.87-1.6%$8.00+1.7%+145.9%$286.89M$59.63M-14.5760News CoverageAnalyst Revision Related Companies and Tools Related Companies TXG Alternatives ALNT Alternatives AEHR Alternatives TRNS Alternatives CTKB Alternatives LAB Alternatives FEIM Alternatives SENS Alternatives QSI Alternatives MASS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
